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Summary.-Survival data of 106 males and 110 females with disseminated malignant
melanoma, recorded between 1956 and 1975, were reviewed. Survival after first
evidence of distant metastasis was significantly longer in women than in men
(P=0.02). There was no difference in survival after occurrence of distant metastasis
between pre- and postmenopausal women, nor between parous and nulliparous
women. However, there was a clear female superiority of premenopausal women
over males <50 years and, to a lesser extent, of postmenopausal women over males
>50 years. It is concluded that endocrine factors enhance melanoma activity in the
male patient. The suggestion that malignant melanoma is "testosterone-dependent"
seems justifiable. A possible explanation is given for the general experience that
women with melanoma show a more favourable response to chemotherapy than men.
FEMALES WITH malignant melanoma
have a more favourable prognosis than
males (White, 1959; Olsen, 1966; Shaw
et al., 1978). This sex influence on survival
is mainly attributed to differences in the
location of the primary, and in the stage
of the disease at first presentation. How-
ever, Shaw et al. (1978) concluded that,
apart from the earlier clinical stage and
the prognostically more favourable an-
atomical sites in women than in men, the
capacity to metastasize is different in the
2 sexes. Female superiority in survival was
only evident prior to manifestation of
metastatic spread; survival rates inwomen
first presenting with melanoma ofStage II
(regional lymphnode metastasis) or Stage
III (disseminated disease) were no differ-
ent from those in the corresponding men.
The same authors also found that their
male patients had a distinctly shorter
duration of symptoms before presentation
and concluded that the disease develops
more rapidly in men. However, estimation
of the period of delay between onset and
diagnosis is unreliable. Also, combining
survival data of Stages II and III melan-
oma patients, without further stratifica-
tion, appearsunjustifiable, asthecategories
studied may not have been comparable.
Definite conclusions about endocrine
influences on the growth rate of human
melanoma cannot be reached from the
literature. In particular, differences in the
late course ofthe disease between men and
women have never been adequately evalu-
ated. Since such information might lead
to important alterations in melanoma
management, this study was planned to
compare survival data of male and
female melanoma patients after first
evidence of distant metastatic spread.
MATERIALS AND METHODS
From 1956 to 1975, 499 patients were regis-
teredattheRotterdamschRadiotherapeutisch
Instituut with cutaneous malignant mela-
noma. The minimum observation period was
30 months. When this study was completed,
163 patients were still alive, and were ex-
cluded. Of the 336 patients who died, a
further 102 cases were excluded for various
reasons (Table I). The patients with in-
sufficient follow-up data include cases with a
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second malignancy (other than basal-cell
carcinoma) who developed metastatic spread,
but who had no autopsy to establish the real
cause ofdeath. All patients who were reported
to have died from "intercurrent diseases" had
no verified active melanoma at the time of
death. Lentigo maligna melanoma was not
considered because of its distinct biological
behaviour (Clark et al., 1969). Since the hist-
ology reports did not always allow a clear
distinction between the different histogenetic
types of melanoma, patients over 50 years of
age with primaries on sun-exposed sites, and
who fulfilled at least one of the following
criteria: (a) minimum duration of symptoms
24 months, and (b) melanoma predominantly
of the spindle-cell type, were also excluded.
The latter category almostcertainlycomprised
lentigo maligna melanomas.
Of the 234 patients who died ofmelanoma,
2 died owing to local or regional disease. The
remaining 232 patients died with distant
metastasis. In 16 cases, accurate survival
data after dissemination could not be ob-
tained from the records. Thus, 216 cases
remained for study: 106 males and 110
females. Survival periods were calculated
from first evidence of distant metastatic
spread till death. Differences in survival
wvere statistically analysed according to the
Mantel test (1966).
RESULTS
Fig. I shows the suirvival curves of male
and female melanoma patients after first
evidence of distant metastatic spread.
Females fared distinctly better than males
(P = 0 02). Since survival was more favour-
able in patients with overt metastasis at
niodal sites or in the skin (soft-tissue
involvement) than in initial spread to
viscera or brain, these categories were
analysed independently (Table II). In the
visceral category, mainly composed of
pulmonary, hepatic and osseous second-
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FIG. 1. -Survival after first, evidence of sys-
temic sprea(l (106 males; 110 females).
TABLE II. Survival according to site of
initial distant metastasis
Nuimber
Site of of patients
first distant I--
metastasis MI F
Soft tissues 33 45
Visceral or osseous 62 52
Cerebral 11 13
Total 106 110
Median
survival
(months)
M F
6 8
3-5 7
4 3
4 7
p
N.S.
0 002>
N.S.
0-02
No treatment
Surgery
Radiotherapy
Chemo- or immunotherapy
Combined modalities
Unknown
33
4
21
14
26
8
F
31
5
21
18
28
7
Total 106 110
aries, disparity between the sexes was
highly significant (P = 0 002).
Since therapeutic measures may in-
fluence survival from metastatic melan-
oma, the treatment modalities used in our
patients were also scrutinized. There was
no definite discrepancy in the type of
treatment for distant metastasis between
male and female patients (Table III). The
effect of diethylimidazole-carboxamide
(DTIC) with or without other chemo- or
immunotherapeutic agents, was evaluated
separately. Females showed a better
response than males: only 3/23 evaluable
male patients (13%) showed a complete
TABLE III. Treatment for distant meta-
stasis
- 3
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response (disappearance of all discernible
tumour for at least 2 months) or a partial
response (> 5000 tumour regression) vs
9/22 females (41o%). When all DTIC-
treated patients were excluded from the
above survival analyses, the observed
trends were unchanged and P values were
still significant.
* - 't '' '- ntft
FIG. 2. Survival after first evidence of dis-
tant metastasis for pre- and postmeno-
pausal women compared to men <50 and
> 50 years. Numbers of patients are given
in parentheses. 0 - 0, F, premeno-
pausal (57); 0 . . . . . .0 F, postmeno-
pausal (53); * *, M <50 yrs (67);
0 . ,M, > 50yrs(38).
Fig. 2 represents the survival curves
after initial presentation with distant
metastasis for pre- and postmenopausal
women. The corresponding survival curves
for males <50 and > 50 years are also
indicated. (One prepubertal male was
excluded.) Whereas pre- and postmeno-
pausal women exhibited similar prognosis
(median survival 8 and 7 months re-
spectively), the difference between pre-
menopausal women and males < 50 years
was significant (median survival 8 and 4
months; P = 0 02). The difference between
postmenopausal women and males > 50
years was noteworthy, though not statis-
tically significant (median survival 7 and
4*5 months). Between males < 50 and > 50
years no difference in survival was
recognized.
The effect of previous pregnancies on
the course of metastatic melanoma was
also evaluated. Survival after first evi-
dence of remote spread was virtually
similar for both parous and nulliparous
women.
The anatomical site of the primary had
no bearing on prognosis once systemic
spread had occurred. For instance, median
survival after dissemination was 4 months
for males with melanomas on the trunk
(n = 54), against 8 months for females
(n = 29). A median survival of 3 months
was observed for males with tumours on
the legs (n = 18), vs 7 months for females
(n= 41).
DISCUSSION
The present study provides circum-
stantial evidence that there are sex-
related factors influencing the late course
of malignant melanoma. Prognosis, once
distant metastasis has occurred, is mark-
edly better in women. Women benefited
more from treatment with DTIC than
men but, when all DTIC-treated patients
were excluded from analysis, the observed
trends were still clearly recognizable.
These data contrast with several reports
in the literature suggesting that sex differ-
ences in prognosis disappear once the
disease has metastasized. Olsen (1966)
emphasized that sex differences in prog-
nosis were not demonstrable after meta-
stasis, and concluded that possible causes
of sex differences in behaviour of melan-
oma should be sought at an early stage of
the disease. Shaw et al. (1978) also inferred
that female superiority in survival was
only present before metastasis. Both
series, however, presented survival rates
for Stages II and III combined, without
further stratification. On the other hand,
the series presented by White (1963)
showed a noticeable, though not signifi-
cant, difference in survival between male
and female patients with disseminated
disease; 8/54 males showed a survival of
more than 5 years, vs 10/37 females.
Survival rates in women are better than
in men mainly because of 2 interrelated
variables: the more favourable site and
the earlier stage at diagnosis in female
patients. Probably, neither of these char-
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acteristics, though sex-related, is endo-
crine in origin. If endocrine factors affect
prognosis, it is conceivable that they
modify the growth rate of melanoma at
all stages. The idea that endocrine in-
fluences delay or promote growth only at
an early stage of the disease should be
viewed with scepticism; the present study
demonstrates that survival after the first
manifestation of distant metastasis is
longer in women than in men.
Several investigators have stressed the
favourable prognosis in premenopausal
compared to postmenopausal women
(Nathanson et al., 1967; McLeod et al.,
1971). This would suggest that malignant
melanoma is an endocrine-dependent
tumour. However, premenopausal women
may seek medical attention when their
primaries are relatively small. Hence, a
better cure rate is to be expected. In our
series, survival after first evidence of
distant spread did not differ between pre-
and postmenopausal women. This indi-
cates that changes in the hormonal status
of the female host exert a negligible effect
on the behaviour of melanoma.
The influence of pregnancy on the prog-
nosis of cutaneous melanoma has been the
subject of several clinical studies (Pack &
Scharnagel, 1951; Greorge et al., 1960;
White et al., 1961; Shinl et al., 1 976). From
these studies it is not clear whether preg-
nancy at the time of diagnosis has an
adverse effect on survival, or not. Note-
worthy are the cases of spontaneous re-
gression after delivery reported by Sumner
(1953) and Allen (1955). Olsen (1966)
described 7 patients with melanoma
activity associated with pregnancy: in
most cases pregnancy had a deleterious
influence on the course of the disease. In
our Institute 11 females were seen with
one or more pregnancies during melanoma
activity (unpublished data). In 5 cases an
exacerbation of melanoma growth was
related to the pregnancy, whereas in 3
patients no such growth stimulation was
apparent. In the remaining 3 cases, the
possible influence of pregnancy was not
evaluable. Although the data from the
literature, together with ouir mnaterial,
relating to pregnancy and melanoma is
principally anecdotal, the suggestion that
pregnancy may exert a sinister influence
on the behaviour of melanoma cannot be
completely discounted.
Reports on the role of previouts preg-
nancies are conflicting (Hersey et al., 1977;
Shaw et al., 1978; Weiss & Flannery,
1978). The effect of previous gestation
might, be immunological (immunization
against tumour-associated foetal anti-
gens?) rather than endocrine (Hersey et
al., 1977). On the other hand, many nulli-
parous patients are unmarried and, for
various reasons, late tumour detection or
delayed doctor's attendance may occur.
This possibly accounts for the better prog-
nosis for parous women in the series of
Hersey et al. (1977) and Shaw et al. (1978).
The present analysis was unable to show
any disparity in survival after evidence of
distant metastasis between parous aiid
nulliparous women.
Age is an important prognostic indi-
cator. In our total series a poorer prog-
nosis was demonstrated for both older
males and females than for the younger
age groups. This could be ascribed to the
later stage of the disease at presentation
in the elderly. In other words, the propor-
tion of patients dying from melanoma is
correlated with age. In patients with
systemic spread no clear age-specific
survival rate was recognized; older males
with metastasis showed similar survival to
younger males, and the same applied for
females. However, females preserved their
advantage over males, irrespective of age.
Our findings may have important, im-
plications. First of all, since survival after
initial distant metastasis was not signifi-
cantly different between pre- and post-
menopausal women, and since survival
was markedly worse in bot,h men of < 50
and > 50 years of age than in pre- and
postmenopausal women, it is concluded
that androgenic steroids may have an
adverse effect. In other words, androgenic
steroids may act as a growth-promoting
factor in malignant melanoma. This theoryF. RAMPEN
contrasts with the speculative view of
Sadoff et al. (1973) concerning oestrogen
dependency. If oestrogens enhanced
tumour growth, males should have a
better prognosis than non-pregnant
females whereas the opposite is the
reality. A more plausible explanation,
therefore, is that androgens have an
adverse effect on prognosis, thus account-
ing for the poor survival in males, and
possibly also in pregnant females, who
secrete considerable quantities of andro-
gens. The deleterious influence of andro-
genic steroids was also suggested by Shiu
et al. (1976). If malignant melanoma is a
"testosterone-dependent" tumour, thera-
peutic trials with anti-androgens or with
orchidectomy in male patients appear
unwarranted. The more so since the male
patient shows minimal benefit from treat-
ment with DTIC, with a high morbidity.
This suggestion is supported by the in-
teresting observation ofHerbst (1943) of a
male patient with melanoma of the
choroid, who experienced definite sub-
jective and objective tumour response
after orchidectomy. Of interest in this
respect is the hybrid fish of the genus
Xiphophorus, studied by Siciliano et al.
(1971) in which the males carry a high risk
of developing melanomas in their lateral
chromophores. The induction and pro-
motion of melanomas is clearly affected
by androgens, since tumours develop only
in the post-pubescent male fish.
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A second implication is the need, in any
clinical trial of surgical, chemo- or im-
munotherapy, to class the patients accord-
ing to sex.
Thirdly, the theory described above
may plausibly explain the difference in
response to chemo- and immunotherapy
between men and women (Comis & Carter,
1974). The sex-related response rate has
baffled many authors, but as yet no
satisfactory explanation has been pro-
vided. Fig. 3 shows a schematic repre-
sentation of the hypothetical growth
curves of 2 patients, a (male) and b
(female), with tumour volume x, after
treatment with DTIC. The straight solid
lines represent, if our concept of a slower
growth rate in women is genuine, the
imaginary growth curves of untreated
male and female patients. Assuming that
the log cell kill after DTIC, and hence the
tumour regression, y, is the same for both
patients, patient a will then be classified
as "progression", since tumour regression
is insufficient to cross the level of stable
disease (S.D.), whereas in patient b the
very same tumour regression will produce
a "partial response" (P.R.).
From the above findings it is suggested
that hormonal influences play a significant
role in the prognosis of cutaneous melan-
oma. Further studies are warranted to
elucidate the relative importance of such
endocrine variables in influencing sur-
vival. It would be interesting to ascertain,
for melanomas of comparable size and
location, whether factors probably repre-
senting different biological behaviour, like
mitotic index (Schmoeckel & Braun-
Falco, 1978), vaso-invasive properties
(Gilchrist et al., 1977) and horizontal vs
vertical growth tendency (Clark et al.,
1975) show any sex differences. To date
there have been few studies of steroid-
hormone receptors in human melanoma
(Fisher et al., 1976; Friedman et al., 1978);
further investigations are needed in this
area. Histochemical and biochemical
studies might help to characterize possible
endocrine pathways by which the be-
haviour of melanoma is modified. More
DTIC
FIe. 3.- Hypothetical representation of res-
ponse to chemotherapy (see text).
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sophisticated and rational treatment
strategies for this capricious neoplasm
might emerge from such stuclies.
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